Mani P, et al. - In this secondary analysis of the VISTA-16 trial, researchers evaluated if longitudinal increases in high-sensitivity C-reactive protein (hsCRP) measurements during the 16 weeks following acute coronary syndrome (ACS) were independently related to a greater risk of a major adverse cardiac event (MACE), all-cause mortality, and cardiovascular mortality. The study sample consisted of 4,257 participants (73.8% men). The mean age of the participants was 60.3 years. Despite established background therapies, a greater risk of the combined MACE end point, cardiovascular death, and all-cause death was observed in relation to initial and subsequent increases in hsCRP levels during 16 weeks post-ACS. Patients at higher risk for mortality and morbidity may be identified with serial measurements of hsCRP during clinical follow-up post-ACS.